Full year revenue and EBITDA in line with expectationsCommitted to becoming a leading, global clinical diagnostics company Paris, France and Camberley, UK – 25 January 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2021, together with a strategy
Visit PageNews and Events
Approval of COVID-19 test in the UK under CTDA legislation
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021
Visit PageApprobation du test COVID-19 au Royaume-Uni dans le cadre de la réglementation adoptée par l’Agence britannique de sécurité sanitaire (“CTDA”)
Approbation du test COVID-19 de genesig® au Royaume-Uni en vertu dela CTDA Paris, France et Camberley, Royaume-Uni – 26 novembre 2021 –Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international dudiagnostic clinique, annonce que, suite à l’annonce du 2 novembre 2021, le test PCR entemps réel genesig® COVID-19 de la société a été
Visit Page